

July 12, 2025

BSE Limited 1 st Floor, P J Towers, Dalal Street, <u>Mumbai-400001</u>	Code: 532321	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), <u>Mumbai-400051</u>	Code: Zyduslife
--	---------------------	---	------------------------

Sub.: Incorporation of a wholly owned subsidiary in the United States of America

- Ref.: 1.** Intimation under regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the **Listing Regulations**") read with SEBI Master Circular dated November 11, 2024, and SEBI Circular dated December 31, 2024 ("the **SEBI Circulars**")
2. Our earlier intimation dated June 3, 2025

Dear Sir / Madam,

In our earlier intimation dated June 3, 2025, it was informed that Zydus Pharmaceuticals USA Inc., USA, ("**ZPUI**") a wholly owned subsidiary of Zydus Lifesciences Limited ("the **Company**") has entered into a definitive agreement with Agenesis West LLC, and Agenesis Inc., USA (collectively referred to as "**Agenesis**"), to acquire, directly or through its affiliates, two U.S. based biologics manufacturing facilities of Agenesis, one in Emeryville, CA and another in Berkeley, CA ("the **Target Assets**").

We hereby now inform that ZPUI has incorporated a wholly owned subsidiary in the name of a Zylidac Bio LLC on July 11, 2025. Zylidac will be acquiring the Target Assets of Agenesis.

Requisite details as required to be disclosed pursuant to the provisions of regulation 30 of the Listing Regulations read with para A of part A of Schedule of the Listing Regulations and para 1.1 of Annexure 18 of the SEBI Circular are provided in **Annexure-"1"**.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO. FCS7063

Encl.: As above

Zydus Lifesciences Limited

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Annexure-“1”

Sr. No.	Particulars	Responses
1.	Name of the target entity, details in brief such as size, turnover etc.:	<p>Name of the entity: Zylidac Bio LLC</p> <p>Turnover: Nil (as Zylidac Bio LLC is yet to commence business operation)</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”:	<p>Zydus Pharmaceuticals USA Inc., USA, a wholly owned subsidiary of Zydus Lifesciences Limited, has incorporated a wholly owned subsidiary in the name of Zylidac Bio LLC. Hence, Zylidac Bio LLC became a related party.</p> <p>Save and except above, the Promoter / Promoter Group / Group Companies are not interested in the said incorporation.</p>
3.	Industry to which the entity being acquired belongs:	Pharmaceuticals
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity):	<p>Zylidac Bio LLC is a pharmaceutical company.</p> <p>The immediate objective of incorporation of Zylidac Bio LLC is to acquire the Target Assets of Agenus.</p>
5.	Brief details of any governmental or regulatory approvals required for the acquisition:	Not applicable
6.	Indicative time period for completion of the acquisition:	Not applicable
7.	Consideration-whether cash consideration or share swap or any other form and details of the same:	LLC type of company in the USA can be incorporated without initial share capital. Hence, Zylidac Bio LLC is incorporated without any consideration amount.



Sr. No.	Particulars	Responses
8.	Cost of acquisition and/or the price at which the shares are acquired:	Please refer reply to Point No. 7 above.
9.	Percentage of shareholding / control acquired and / or number of shares acquired:	Zylidac Bio LLC is a wholly owned subsidiary of Zydus Pharmaceuticals USA Inc., USA.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief):	Zylidac Bio LLC is incorporated in the United States of America on July 11, 2025, and is yet to commence its business operation.

For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO. FCS7063

